HighVista Strategies LLC Invests $603,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

HighVista Strategies LLC purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,743 shares of the company’s stock, valued at approximately $603,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Comerica Bank increased its stake in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares in the last quarter. Keudell Morrison Wealth Management boosted its stake in shares of Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock worth $212,000 after acquiring an additional 480 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Kymera Therapeutics in the 3rd quarter valued at $61,000.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 15.82% of the company’s stock.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research reports. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $38.00 to $57.00 in a report on Monday. UBS Group dropped their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Oppenheimer upped their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Finally, Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price target for the company. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.40.

Kymera Therapeutics Trading Up 1.9 %

NASDAQ KYMR opened at $47.74 on Tuesday. The stock has a fifty day simple moving average of $46.82 and a 200-day simple moving average of $42.26. The stock has a market cap of $3.09 billion, a PE ratio of -20.40 and a beta of 2.16. Kymera Therapeutics, Inc. has a twelve month low of $20.32 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the prior year, the company posted ($0.90) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 20.9% compared to the same quarter last year. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.